ArticleEinstein (Sao Paulo, Brazil)2022
Real world evidence of the use of metamizole (dipyrone) by the Brazilian population. A retrospective cohort with over 380,000 patients.
Article in Einstein (Sao Paulo, Brazil), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Adverse effects of dipyrone (Metamizole) use during pregnancy on offspring health: a systematic review and meta-analysis.BMC pregnancy and childbirth · 2025Pooled it
- Hematological parameters in patients with chronic pain on long-term dipyrone therapy followed in a tertiary hospital: a retrospective cohort study.Clinics (Sao Paulo, Brazil) · 2026Article
- Maternal Dipyrone Exposure and Risk of Major Congenital Malformations, Adverse Perinatal and Postnatal Outcomes: A Population-Based Cohort Study.Clinical pharmacology and therapeutics · 2026Article
- Analgesic efficacy of oral tramadol-dipyrone combination in cats undergoing ovariohysterectomy.Frontiers in veterinary science · 2026Article
- Dipyrone use in Brazil: clinical conditions, sociodemographic characteristics, population attitudes and perceptions.Cadernos de saude publica · 2026Article
- Antinociceptive and anti-inflammatory effects of a formulation based onJournal of oral & facial pain and headache · 2025Article
- The effect of methadone and ketamine on quality of recovery in patients undergoing laparoscopic cholecystectomy: a prospective cohort study.Sao Paulo medical journal = Revista paulista de medicina · 2025Article
- Review of Challenges in Performing Real-World Evidence Studies for Nonprescription Products.Pragmatic and observational research · 2025Review
- Influence of Metamizole on Antitumour Activity of Risedronate Sodium in In Vitro Studies on Canine (D-17) and Human (U-2 OS) Osteosarcoma Cell Lines.Biomedicines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine under which health conditions metamizole (dipyrone) is used as a single drug or as fixed-dose combination.
methodsTwo retrospective cohorts of Brazilian patients treated with metamizole between January 2015 and December 2017 were analyzed: a metamizole-based cohort (Cohort 1) and a symptoms-based cohort (Cohort 2). Anonymized patient data was obtained from Amil Clinical Data Warehouse. The number of patients with symptoms was described by age and sex.
resultsThe sample size of the two cohorts consisted of 384,668 patients. In patients using metamizole (Cohort 1), the most common reason for medication was the treatment of some form of pain (81%), followed by fever (19%). Headache was the most common (19%) specified pain class, followed by sore throat (8%), muscular pain (6%), and abdominal pain (5%). In adult patients (n=276,279; 71.8%), metamizole was used as a monotherapy or associated with another drug, for any sort of pain, in over 88% of the patients. General pain was the main reason for metamizole use in children (61%).
conclusionReal world evidence to evaluate Brazilian patients' therapeutic options is unusual and yet to be more explored using digital tools enabling better data registration. The present study confirmed that metamizole is widely used as a non-anti-inflammatory drug, and also showed the management of pain and fever as the most frequent indications in all age groups studied.Registry in Clinical Trials Database: REBEC Database: 10507.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.